Abstract: Ophthalmic formulations comprising aflibercept and a lysine salt tonicifying agent are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

Abstract: The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.

Abstract: Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

Abstract: Ophthalmic formulations comprising aflibercept and a lysine salt tonicifying agent are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or t

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or to

Abstract: The present invention relates to a hemoglobin compositions stabilized against the formation of aggregates. The present invention further relates to methods of making such hemoglobin compositions.

Abstract: The present invention relates to globins containing non-naturally occurring binding domains, In particular, the present invention is directed toward a binding domain comprising the oligomerizing domain GCN4 and GCN4 derivatives. Thc present invention also relates to multimeric hemoglobins comprised of at least one globin containing at least one non-naturally occurring binding domain.

Abstract: The present invention relates to cross-linked hemoglobins, and particularly to methods of controlling the functionality of such hemoglobins. The controlled functionalities include the P.sub.50 and the Hill coefficient. The present invention provides methods for producing a cross-linked hemoglobin with specific final functionalities by regulating the amount of both total hemoglobin and R-state hemoglobin prior to cross-linking, and by modulating cross-linking reaction conditions such as time, temperature, pH and the ratio of cross-linking reagent to hemoglobin.

Abstract: The present invention relates to modified hemoglobin-like polypeptides containing multiple dialpha (or dibeta) domains. The present invention also relates to multimeric hemoglobin-like proteins comprising covalently joined hemoglobin-like moieties. Another aspect of the inention is directed at a purification method of hemoglobin-like polypeptides utilizing ion exchange chromatography.

Abstract: The present invention relates to storage stable hemoglobin solutions which contain partially deoxygenated and surprisingly low amounts of reducing agents. Methods for preparing such storage stable hemoglobin solutions are also provided as well as a systems for storing the solutions.

Abstract: The present invention relates to hemoglobin compositions stabilized against the formation of aggregates. Such compositions contain at least a surfactant, said surfactant not being an adduct of a polymer and an anionic ligand. The present invention further relates to methods of making such hemoglobin compositions.